Global Monoclonal Antibodies (mAbs) Biosimilars Market Growth (Status and Outlook) 2026-2032
The global Monoclonal Antibodies (mAbs) Biosimilars market size is predicted to grow from US$ 14625 million in 2025 to US$ 47680 million in 2032; it is expected to grow at a CAGR of 17.8% from 2026 to 2032.
Monoclonal antibody (mAb) biosimilars are highly similar, lower-cost versions of approved, brand-name biological drugs used to treat cancers, autoimmune diseases, and infections. They are developed after a reference mAb's patent expires and are proven to have no clinically meaningful differences in efficacy, safety, or quality compared to the original, providing greater patient access to advanced therapies.
The global supply structure has become increasingly multi-polar. SouthKorean companies such as Celltrion and SamsungBioepis have built broad, globally visible portfolios across immunology, oncology, ophthalmology and hematology. Large western pharmaceutical and generic groups such as Amgen, Pfizer, Sandoz, FreseniusKabi, Organon and BoehringerIngelheim compete through regulatory scale, commercialization networks and established healthcare-system access. Indian companies such as BioconBiologics, Dr.Reddy?s, Intas/Accord and Lupin combine cost-competitive development with growing regulated-market ambitions. Chinese companies such as Henlius, Bio-Thera, Qilu and Innovent are moving from domestic approvals toward international filings and licensing partnerships. The market is also shaped by partnership models, such as Alvotech/Teva, Formycon/FreseniusKabi, Bio-Thera/STADA and Bio-Thera/GedeonRichter, where one party often leads development and manufacturing while another leads regional commercialization.
Demand growth is being driven by the expansion of biosimilar competition into high-spend reference biologics. The first major wave centered on oncology and immunology products such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab. The next wave is expanding into ustekinumab, tocilizumab, ranibizumab, aflibercept, denosumab, eculizumab, omalizumab and other antibody-related products. However, regulatory approval alone does not guarantee rapid uptake. The ASPE report on U.S. biosimilar market entry highlights that market size and entry order affect biosimilar revenues, and that markets such as bevacizumab, rituximab and trastuzumab took time to reach peak biosimilar share. In practice, adoption depends on payer policy, tendering rules, formulary access, physician confidence, patient switching, interchangeability status, originator contracting and supply reliability.
From a product and strategy perspective, the market is moving beyond simple ?first biosimilar to a blockbuster mAb? competition. Future differentiation will increasingly depend on high-concentration formulations, citrate-free presentations, prefilled syringes, autoinjectors, interchangeability designations, global dossier reuse, real-world evidence, manufacturing cost control and broad market-access execution. The U.S. and Europe will remain the most valuable regulated markets, but China, India, Latin America, the Middle East and Southeast Asia are increasingly important for volume growth and regional commercialization partnerships. The long-term outlook is positive because many high-value biologics are entering or approaching biosimilar competition, but price erosion can be severe once multiple entrants compete. Companies with integrated R&D, manufacturing, regulatory and commercialization capabilities are therefore better positioned than firms that rely only on low-cost production or single-market approvals.
LPI (LP Information)' newest research report, the ?Monoclonal Antibodies (mAbs) Biosimilars Industry Forecast? looks at past sales and reviews total world Monoclonal Antibodies (mAbs) Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibodies (mAbs) Biosimilars sales for 2026 through 2032. With Monoclonal Antibodies (mAbs) Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibodies (mAbs) Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Monoclonal Antibodies (mAbs) Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Monoclonal Antibodies (mAbs) Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Monoclonal Antibodies (mAbs) Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibodies (mAbs) Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibodies (mAbs) Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibodies (mAbs) Biosimilars market by product type, application, key players and key regions and countries.
Segmentation by Type:
Monoclonal antibody (mAb) biosimilars are highly similar, lower-cost versions of approved, brand-name biological drugs used to treat cancers, autoimmune diseases, and infections. They are developed after a reference mAb's patent expires and are proven to have no clinically meaningful differences in efficacy, safety, or quality compared to the original, providing greater patient access to advanced therapies.
The global supply structure has become increasingly multi-polar. SouthKorean companies such as Celltrion and SamsungBioepis have built broad, globally visible portfolios across immunology, oncology, ophthalmology and hematology. Large western pharmaceutical and generic groups such as Amgen, Pfizer, Sandoz, FreseniusKabi, Organon and BoehringerIngelheim compete through regulatory scale, commercialization networks and established healthcare-system access. Indian companies such as BioconBiologics, Dr.Reddy?s, Intas/Accord and Lupin combine cost-competitive development with growing regulated-market ambitions. Chinese companies such as Henlius, Bio-Thera, Qilu and Innovent are moving from domestic approvals toward international filings and licensing partnerships. The market is also shaped by partnership models, such as Alvotech/Teva, Formycon/FreseniusKabi, Bio-Thera/STADA and Bio-Thera/GedeonRichter, where one party often leads development and manufacturing while another leads regional commercialization.
Demand growth is being driven by the expansion of biosimilar competition into high-spend reference biologics. The first major wave centered on oncology and immunology products such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab. The next wave is expanding into ustekinumab, tocilizumab, ranibizumab, aflibercept, denosumab, eculizumab, omalizumab and other antibody-related products. However, regulatory approval alone does not guarantee rapid uptake. The ASPE report on U.S. biosimilar market entry highlights that market size and entry order affect biosimilar revenues, and that markets such as bevacizumab, rituximab and trastuzumab took time to reach peak biosimilar share. In practice, adoption depends on payer policy, tendering rules, formulary access, physician confidence, patient switching, interchangeability status, originator contracting and supply reliability.
From a product and strategy perspective, the market is moving beyond simple ?first biosimilar to a blockbuster mAb? competition. Future differentiation will increasingly depend on high-concentration formulations, citrate-free presentations, prefilled syringes, autoinjectors, interchangeability designations, global dossier reuse, real-world evidence, manufacturing cost control and broad market-access execution. The U.S. and Europe will remain the most valuable regulated markets, but China, India, Latin America, the Middle East and Southeast Asia are increasingly important for volume growth and regional commercialization partnerships. The long-term outlook is positive because many high-value biologics are entering or approaching biosimilar competition, but price erosion can be severe once multiple entrants compete. Companies with integrated R&D, manufacturing, regulatory and commercialization capabilities are therefore better positioned than firms that rely only on low-cost production or single-market approvals.
LPI (LP Information)' newest research report, the ?Monoclonal Antibodies (mAbs) Biosimilars Industry Forecast? looks at past sales and reviews total world Monoclonal Antibodies (mAbs) Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibodies (mAbs) Biosimilars sales for 2026 through 2032. With Monoclonal Antibodies (mAbs) Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibodies (mAbs) Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Monoclonal Antibodies (mAbs) Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Monoclonal Antibodies (mAbs) Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Monoclonal Antibodies (mAbs) Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibodies (mAbs) Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibodies (mAbs) Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibodies (mAbs) Biosimilars market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Adalimumab Biosimilars
- Infliximab Biosimilars
- Rituximab Biosimilars
- Trastuzumab Biosimilars
- Bevacizumab Biosimilars
- Ranibizumab Biosimilars
- Ustekinumab Biosimilars
- Tocilizumab Biosimilars
- Denosumab Biosimilars
- Other mAb Biosimilars
- Intravenous Infusion Vials
- Subcutaneous Prefilled Syringes
- Autoinjectors
- Lyophilized Powder for Injection
- Concentrate for Solution for Infusion
- Ophthalmic Intravitreal Injection
- Multiple Presentations
- TNF-? Inhibitors
- CD20-targeting Antibodies
- HER2-targeting Antibodies
- VEGF/VEGF-A Inhibitors
- IL-6R Inhibitors
- IL-12/23 Inhibitors
- RANKL Inhibitors
- C5 Complement Inhibitors
- IgE Inhibitors
- Other Targets
- Oncology
- Autoimmune and Inflammatory Diseases
- Ophthalmology
- Bone Disease and Osteoporosis
- Hematology and Rare Diseases
- Asthma and Allergy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Celltrion,Inc.
- SamsungBioepisCo.,Ltd.
- AmgenInc.
- SandozGroupAG
- PfizerInc.
- BioconBiologicsLimited
- FreseniusKabiAG
- FormyconAG
- Alvotech
- TevaPharmaceuticalIndustriesLtd.
- Organon&Co.
- BoehringerIngelheimInternationalGmbH
- CoherusBioSciences,Inc.
- mAbxience
- STADAArzneimittelAG
- GedeonRichterPlc.
- Bio-TheraSolutions,Ltd.
- ShanghaiHenliusBiotech,Inc.
- QiluPharmaceuticalCo.,Ltd.
- InnoventBiologics,Inc.
- Dr.Reddy?sLaboratoriesLtd.
- IntasPharmaceuticalsLtd.
- AccordHealthcare
- LupinLimited
- ZydusLifesciencesLimited
- RelianceLifeSciencesPvt.Ltd.
- PrestigeBiopharmaLimited
- AmnealPharmaceuticals,Inc.
- PolpharmaBiologicsB.V.
- Mabwell(Shanghai)BioscienceCo.,Ltd.
- ZhejiangHisunPharmaceuticalCo.,Ltd.
- JiangsuHengruiPharmaceuticalsCo.,Ltd.
- LivzonPharmaceuticalGroupInc.
- SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
- MabpharmLimited
- BioXpressTherapeuticsSA
- TanvexBioPharma,Inc.
- CelltrionHealthcare
- AmegaBiotech
- ProbiomedS.A.deC.V.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size (2021-2032)
2.1.2 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Monoclonal Antibodies (mAbs) Biosimilars by Country/Region (2021, 2025 & 2032)
2.2 Monoclonal Antibodies (mAbs) Biosimilars Segment by Type
2.2.1 Adalimumab Biosimilars
2.2.2 Infliximab Biosimilars
2.2.3 Rituximab Biosimilars
2.2.4 Trastuzumab Biosimilars
2.2.5 Bevacizumab Biosimilars
2.2.6 Ranibizumab Biosimilars
2.2.7 Ustekinumab Biosimilars
2.2.8 Tocilizumab Biosimilars
2.2.9 Denosumab Biosimilars
2.2.10 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type
2.2.10.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.10.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
2.3 Monoclonal Antibodies (mAbs) Biosimilars Segment by Dosage Form
2.3.1 Intravenous Infusion Vials
2.3.2 Subcutaneous Prefilled Syringes
2.3.3 Autoinjectors
2.3.4 Lyophilized Powder for Injection
2.3.5 Concentrate for Solution for Infusion
2.3.6 Ophthalmic Intravitreal Injection
2.3.7 Multiple Presentations
2.3.8 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form
2.3.8.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Dosage Form (2021 VS 2025 VS 2032)
2.3.8.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form (2021-2026)
2.4 Monoclonal Antibodies (mAbs) Biosimilars Segment by Molecular Target
2.4.1 TNF-? Inhibitors
2.4.2 CD20-targeting Antibodies
2.4.3 HER2-targeting Antibodies
2.4.4 VEGF/VEGF-A Inhibitors
2.4.5 IL-6R Inhibitors
2.4.6 IL-12/23 Inhibitors
2.4.7 RANKL Inhibitors
2.4.8 C5 Complement Inhibitors
2.4.9 IgE Inhibitors
2.4.10 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target
2.4.10.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Molecular Target (2021 VS 2025 VS 2032)
2.4.10.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target (2021-2026)
2.5 Monoclonal Antibodies (mAbs) Biosimilars Segment by Application
2.5.1 Oncology
2.5.2 Autoimmune and Inflammatory Diseases
2.5.3 Ophthalmology
2.5.4 Bone Disease and Osteoporosis
2.5.5 Hematology and Rare Diseases
2.5.6 Asthma and Allergy
2.5.7 Other
2.5.8 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application
2.5.8.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.8.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
3 MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS MARKET SIZE BY PLAYER
3.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Player
3.1.1 Global Monoclonal Antibodies (mAbs) Biosimilars Revenue by Player (2021-2026)
3.1.2 Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Player (2021-2026)
3.2 Global Monoclonal Antibodies (mAbs) Biosimilars Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS BY REGION
4.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026)
4.2 Global Monoclonal Antibodies (mAbs) Biosimilars Annual Revenue by Country/Region (2021-2026)
4.3 Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth (2021-2026)
4.4 APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth (2021-2026)
4.5 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth (2021-2026)
4.6 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country (2021-2026)
5.2 Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
5.3 Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026)
6.2 APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
6.3 APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country (2021-2026)
7.2 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
7.3 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars by Region (2021-2026)
8.2 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
8.3 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS MARKET FORECAST
10.1 Global Monoclonal Antibodies (mAbs) Biosimilars Forecast by Region (2027-2032)
10.1.1 Global Monoclonal Antibodies (mAbs) Biosimilars Forecast by Region (2027-2032)
10.1.2 Americas Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.1.3 APAC Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.1.4 Europe Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.1.5 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.2 Americas Monoclonal Antibodies (mAbs) Biosimilars Forecast by Country (2027-2032)
10.2.1 United States Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.2.2 Canada Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.2.3 Mexico Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.2.4 Brazil Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3 APAC Monoclonal Antibodies (mAbs) Biosimilars Forecast by Region (2027-2032)
10.3.1 China Monoclonal Antibodies (mAbs) Biosimilars Market Forecast
10.3.2 Japan Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3.3 Korea Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3.4 Southeast Asia Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3.5 India Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3.6 Australia Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4 Europe Monoclonal Antibodies (mAbs) Biosimilars Forecast by Country (2027-2032)
10.4.1 Germany Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4.2 France Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4.3 UK Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4.4 Italy Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4.5 Russia Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.5 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Forecast by Region (2027-2032)
10.5.1 Egypt Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.5.2 South Africa Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.5.3 Israel Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.5.4 Turkey Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.6 Global Monoclonal Antibodies (mAbs) Biosimilars Forecast by Type (2027-2032)
10.7 Global Monoclonal Antibodies (mAbs) Biosimilars Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
11 KEY PLAYERS ANALYSIS
11.1 Celltrion,Inc.
11.1.1 Celltrion,Inc. Company Information
11.1.2 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.1.3 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Celltrion,Inc. Main Business Overview
11.1.5 Celltrion,Inc. Latest Developments
11.2 SamsungBioepisCo.,Ltd.
11.2.1 SamsungBioepisCo.,Ltd. Company Information
11.2.2 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.2.3 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 SamsungBioepisCo.,Ltd. Main Business Overview
11.2.5 SamsungBioepisCo.,Ltd. Latest Developments
11.3 AmgenInc.
11.3.1 AmgenInc. Company Information
11.3.2 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.3.3 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 AmgenInc. Main Business Overview
11.3.5 AmgenInc. Latest Developments
11.4 SandozGroupAG
11.4.1 SandozGroupAG Company Information
11.4.2 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.4.3 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 SandozGroupAG Main Business Overview
11.4.5 SandozGroupAG Latest Developments
11.5 PfizerInc.
11.5.1 PfizerInc. Company Information
11.5.2 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.5.3 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 PfizerInc. Main Business Overview
11.5.5 PfizerInc. Latest Developments
11.6 BioconBiologicsLimited
11.6.1 BioconBiologicsLimited Company Information
11.6.2 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.6.3 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 BioconBiologicsLimited Main Business Overview
11.6.5 BioconBiologicsLimited Latest Developments
11.7 FreseniusKabiAG
11.7.1 FreseniusKabiAG Company Information
11.7.2 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.7.3 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 FreseniusKabiAG Main Business Overview
11.7.5 FreseniusKabiAG Latest Developments
11.8 FormyconAG
11.8.1 FormyconAG Company Information
11.8.2 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.8.3 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 FormyconAG Main Business Overview
11.8.5 FormyconAG Latest Developments
11.9 Alvotech
11.9.1 Alvotech Company Information
11.9.2 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.9.3 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Alvotech Main Business Overview
11.9.5 Alvotech Latest Developments
11.10 TevaPharmaceuticalIndustriesLtd.
11.10.1 TevaPharmaceuticalIndustriesLtd. Company Information
11.10.2 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.10.3 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 TevaPharmaceuticalIndustriesLtd. Main Business Overview
11.10.5 TevaPharmaceuticalIndustriesLtd. Latest Developments
11.11 Organon&Co.
11.11.1 Organon&Co. Company Information
11.11.2 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.11.3 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Organon&Co. Main Business Overview
11.11.5 Organon&Co. Latest Developments
11.12 BoehringerIngelheimInternationalGmbH
11.12.1 BoehringerIngelheimInternationalGmbH Company Information
11.12.2 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.12.3 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 BoehringerIngelheimInternationalGmbH Main Business Overview
11.12.5 BoehringerIngelheimInternationalGmbH Latest Developments
11.13 CoherusBioSciences,Inc.
11.13.1 CoherusBioSciences,Inc. Company Information
11.13.2 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.13.3 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 CoherusBioSciences,Inc. Main Business Overview
11.13.5 CoherusBioSciences,Inc. Latest Developments
11.14 mAbxience
11.14.1 mAbxience Company Information
11.14.2 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.14.3 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 mAbxience Main Business Overview
11.14.5 mAbxience Latest Developments
11.15 STADAArzneimittelAG
11.15.1 STADAArzneimittelAG Company Information
11.15.2 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.15.3 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 STADAArzneimittelAG Main Business Overview
11.15.5 STADAArzneimittelAG Latest Developments
11.16 GedeonRichterPlc.
11.16.1 GedeonRichterPlc. Company Information
11.16.2 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.16.3 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 GedeonRichterPlc. Main Business Overview
11.16.5 GedeonRichterPlc. Latest Developments
11.17 Bio-TheraSolutions,Ltd.
11.17.1 Bio-TheraSolutions,Ltd. Company Information
11.17.2 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.17.3 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Bio-TheraSolutions,Ltd. Main Business Overview
11.17.5 Bio-TheraSolutions,Ltd. Latest Developments
11.18 ShanghaiHenliusBiotech,Inc.
11.18.1 ShanghaiHenliusBiotech,Inc. Company Information
11.18.2 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.18.3 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 ShanghaiHenliusBiotech,Inc. Main Business Overview
11.18.5 ShanghaiHenliusBiotech,Inc. Latest Developments
11.19 QiluPharmaceuticalCo.,Ltd.
11.19.1 QiluPharmaceuticalCo.,Ltd. Company Information
11.19.2 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.19.3 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 QiluPharmaceuticalCo.,Ltd. Main Business Overview
11.19.5 QiluPharmaceuticalCo.,Ltd. Latest Developments
11.20 InnoventBiologics,Inc.
11.20.1 InnoventBiologics,Inc. Company Information
11.20.2 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.20.3 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 InnoventBiologics,Inc. Main Business Overview
11.20.5 InnoventBiologics,Inc. Latest Developments
11.21 Dr.Reddy?sLaboratoriesLtd.
11.21.1 Dr.Reddy?sLaboratoriesLtd. Company Information
11.21.2 Dr.Reddy?sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.21.3 Dr.Reddy?sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Dr.Reddy?sLaboratoriesLtd. Main Business Overview
11.21.5 Dr.Reddy?sLaboratoriesLtd. Latest Developments
11.22 IntasPharmaceuticalsLtd.
11.22.1 IntasPharmaceuticalsLtd. Company Information
11.22.2 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.22.3 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 IntasPharmaceuticalsLtd. Main Business Overview
11.22.5 IntasPharmaceuticalsLtd. Latest Developments
11.23 AccordHealthcare
11.23.1 AccordHealthcare Company Information
11.23.2 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.23.3 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 AccordHealthcare Main Business Overview
11.23.5 AccordHealthcare Latest Developments
11.24 LupinLimited
11.24.1 LupinLimited Company Information
11.24.2 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.24.3 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 LupinLimited Main Business Overview
11.24.5 LupinLimited Latest Developments
11.25 ZydusLifesciencesLimited
11.25.1 ZydusLifesciencesLimited Company Information
11.25.2 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.25.3 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 ZydusLifesciencesLimited Main Business Overview
11.25.5 ZydusLifesciencesLimited Latest Developments
11.26 RelianceLifeSciencesPvt.Ltd.
11.26.1 RelianceLifeSciencesPvt.Ltd. Company Information
11.26.2 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.26.3 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.26.4 RelianceLifeSciencesPvt.Ltd. Main Business Overview
11.26.5 RelianceLifeSciencesPvt.Ltd. Latest Developments
11.27 PrestigeBiopharmaLimited
11.27.1 PrestigeBiopharmaLimited Company Information
11.27.2 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.27.3 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.27.4 PrestigeBiopharmaLimited Main Business Overview
11.27.5 PrestigeBiopharmaLimited Latest Developments
11.28 AmnealPharmaceuticals,Inc.
11.28.1 AmnealPharmaceuticals,Inc. Company Information
11.28.2 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.28.3 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.28.4 AmnealPharmaceuticals,Inc. Main Business Overview
11.28.5 AmnealPharmaceuticals,Inc. Latest Developments
11.29 PolpharmaBiologicsB.V.
11.29.1 PolpharmaBiologicsB.V. Company Information
11.29.2 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.29.3 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.29.4 PolpharmaBiologicsB.V. Main Business Overview
11.29.5 PolpharmaBiologicsB.V. Latest Developments
11.30 Mabwell(Shanghai)BioscienceCo.,Ltd.
11.30.1 Mabwell(Shanghai)BioscienceCo.,Ltd. Company Information
11.30.2 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.30.3 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.30.4 Mabwell(Shanghai)BioscienceCo.,Ltd. Main Business Overview
11.30.5 Mabwell(Shanghai)BioscienceCo.,Ltd. Latest Developments
11.31 ZhejiangHisunPharmaceuticalCo.,Ltd.
11.31.1 ZhejiangHisunPharmaceuticalCo.,Ltd. Company Information
11.31.2 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.31.3 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.31.4 ZhejiangHisunPharmaceuticalCo.,Ltd. Main Business Overview
11.31.5 ZhejiangHisunPharmaceuticalCo.,Ltd. Latest Developments
11.32 JiangsuHengruiPharmaceuticalsCo.,Ltd.
11.32.1 JiangsuHengruiPharmaceuticalsCo.,Ltd. Company Information
11.32.2 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.32.3 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.32.4 JiangsuHengruiPharmaceuticalsCo.,Ltd. Main Business Overview
11.32.5 JiangsuHengruiPharmaceuticalsCo.,Ltd. Latest Developments
11.33 LivzonPharmaceuticalGroupInc.
11.33.1 LivzonPharmaceuticalGroupInc. Company Information
11.33.2 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.33.3 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.33.4 LivzonPharmaceuticalGroupInc. Main Business Overview
11.33.5 LivzonPharmaceuticalGroupInc. Latest Developments
11.34 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
11.34.1 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Company Information
11.34.2 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.34.3 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.34.4 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Main Business Overview
11.34.5 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Latest Developments
11.35 MabpharmLimited
11.35.1 MabpharmLimited Company Information
11.35.2 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.35.3 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.35.4 MabpharmLimited Main Business Overview
11.35.5 MabpharmLimited Latest Developments
11.36 BioXpressTherapeuticsSA
11.36.1 BioXpressTherapeuticsSA Company Information
11.36.2 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.36.3 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.36.4 BioXpressTherapeuticsSA Main Business Overview
11.36.5 BioXpressTherapeuticsSA Latest Developments
11.37 TanvexBioPharma,Inc.
11.37.1 TanvexBioPharma,Inc. Company Information
11.37.2 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.37.3 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.37.4 TanvexBioPharma,Inc. Main Business Overview
11.37.5 TanvexBioPharma,Inc. Latest Developments
11.38 CelltrionHealthcare
11.38.1 CelltrionHealthcare Company Information
11.38.2 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.38.3 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.38.4 CelltrionHealthcare Main Business Overview
11.38.5 CelltrionHealthcare Latest Developments
11.39 AmegaBiotech
11.39.1 AmegaBiotech Company Information
11.39.2 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.39.3 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.39.4 AmegaBiotech Main Business Overview
11.39.5 AmegaBiotech Latest Developments
11.40 ProbiomedS.A.deC.V.
11.40.1 ProbiomedS.A.deC.V. Company Information
11.40.2 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.40.3 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.40.4 ProbiomedS.A.deC.V. Main Business Overview
11.40.5 ProbiomedS.A.deC.V. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size (2021-2032)
2.1.2 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Monoclonal Antibodies (mAbs) Biosimilars by Country/Region (2021, 2025 & 2032)
2.2 Monoclonal Antibodies (mAbs) Biosimilars Segment by Type
2.2.1 Adalimumab Biosimilars
2.2.2 Infliximab Biosimilars
2.2.3 Rituximab Biosimilars
2.2.4 Trastuzumab Biosimilars
2.2.5 Bevacizumab Biosimilars
2.2.6 Ranibizumab Biosimilars
2.2.7 Ustekinumab Biosimilars
2.2.8 Tocilizumab Biosimilars
2.2.9 Denosumab Biosimilars
2.2.10 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type
2.2.10.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.10.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
2.3 Monoclonal Antibodies (mAbs) Biosimilars Segment by Dosage Form
2.3.1 Intravenous Infusion Vials
2.3.2 Subcutaneous Prefilled Syringes
2.3.3 Autoinjectors
2.3.4 Lyophilized Powder for Injection
2.3.5 Concentrate for Solution for Infusion
2.3.6 Ophthalmic Intravitreal Injection
2.3.7 Multiple Presentations
2.3.8 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form
2.3.8.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Dosage Form (2021 VS 2025 VS 2032)
2.3.8.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form (2021-2026)
2.4 Monoclonal Antibodies (mAbs) Biosimilars Segment by Molecular Target
2.4.1 TNF-? Inhibitors
2.4.2 CD20-targeting Antibodies
2.4.3 HER2-targeting Antibodies
2.4.4 VEGF/VEGF-A Inhibitors
2.4.5 IL-6R Inhibitors
2.4.6 IL-12/23 Inhibitors
2.4.7 RANKL Inhibitors
2.4.8 C5 Complement Inhibitors
2.4.9 IgE Inhibitors
2.4.10 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target
2.4.10.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Molecular Target (2021 VS 2025 VS 2032)
2.4.10.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target (2021-2026)
2.5 Monoclonal Antibodies (mAbs) Biosimilars Segment by Application
2.5.1 Oncology
2.5.2 Autoimmune and Inflammatory Diseases
2.5.3 Ophthalmology
2.5.4 Bone Disease and Osteoporosis
2.5.5 Hematology and Rare Diseases
2.5.6 Asthma and Allergy
2.5.7 Other
2.5.8 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application
2.5.8.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.8.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
3 MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS MARKET SIZE BY PLAYER
3.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Player
3.1.1 Global Monoclonal Antibodies (mAbs) Biosimilars Revenue by Player (2021-2026)
3.1.2 Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Player (2021-2026)
3.2 Global Monoclonal Antibodies (mAbs) Biosimilars Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS BY REGION
4.1 Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026)
4.2 Global Monoclonal Antibodies (mAbs) Biosimilars Annual Revenue by Country/Region (2021-2026)
4.3 Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth (2021-2026)
4.4 APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth (2021-2026)
4.5 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth (2021-2026)
4.6 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country (2021-2026)
5.2 Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
5.3 Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026)
6.2 APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
6.3 APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country (2021-2026)
7.2 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
7.3 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars by Region (2021-2026)
8.2 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
8.3 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS MARKET FORECAST
10.1 Global Monoclonal Antibodies (mAbs) Biosimilars Forecast by Region (2027-2032)
10.1.1 Global Monoclonal Antibodies (mAbs) Biosimilars Forecast by Region (2027-2032)
10.1.2 Americas Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.1.3 APAC Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.1.4 Europe Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.1.5 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.2 Americas Monoclonal Antibodies (mAbs) Biosimilars Forecast by Country (2027-2032)
10.2.1 United States Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.2.2 Canada Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.2.3 Mexico Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.2.4 Brazil Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3 APAC Monoclonal Antibodies (mAbs) Biosimilars Forecast by Region (2027-2032)
10.3.1 China Monoclonal Antibodies (mAbs) Biosimilars Market Forecast
10.3.2 Japan Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3.3 Korea Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3.4 Southeast Asia Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3.5 India Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.3.6 Australia Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4 Europe Monoclonal Antibodies (mAbs) Biosimilars Forecast by Country (2027-2032)
10.4.1 Germany Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4.2 France Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4.3 UK Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4.4 Italy Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.4.5 Russia Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.5 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Forecast by Region (2027-2032)
10.5.1 Egypt Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.5.2 South Africa Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.5.3 Israel Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.5.4 Turkey Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
10.6 Global Monoclonal Antibodies (mAbs) Biosimilars Forecast by Type (2027-2032)
10.7 Global Monoclonal Antibodies (mAbs) Biosimilars Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Monoclonal Antibodies (mAbs) Biosimilars Forecast
11 KEY PLAYERS ANALYSIS
11.1 Celltrion,Inc.
11.1.1 Celltrion,Inc. Company Information
11.1.2 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.1.3 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Celltrion,Inc. Main Business Overview
11.1.5 Celltrion,Inc. Latest Developments
11.2 SamsungBioepisCo.,Ltd.
11.2.1 SamsungBioepisCo.,Ltd. Company Information
11.2.2 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.2.3 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 SamsungBioepisCo.,Ltd. Main Business Overview
11.2.5 SamsungBioepisCo.,Ltd. Latest Developments
11.3 AmgenInc.
11.3.1 AmgenInc. Company Information
11.3.2 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.3.3 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 AmgenInc. Main Business Overview
11.3.5 AmgenInc. Latest Developments
11.4 SandozGroupAG
11.4.1 SandozGroupAG Company Information
11.4.2 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.4.3 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 SandozGroupAG Main Business Overview
11.4.5 SandozGroupAG Latest Developments
11.5 PfizerInc.
11.5.1 PfizerInc. Company Information
11.5.2 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.5.3 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 PfizerInc. Main Business Overview
11.5.5 PfizerInc. Latest Developments
11.6 BioconBiologicsLimited
11.6.1 BioconBiologicsLimited Company Information
11.6.2 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.6.3 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 BioconBiologicsLimited Main Business Overview
11.6.5 BioconBiologicsLimited Latest Developments
11.7 FreseniusKabiAG
11.7.1 FreseniusKabiAG Company Information
11.7.2 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.7.3 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 FreseniusKabiAG Main Business Overview
11.7.5 FreseniusKabiAG Latest Developments
11.8 FormyconAG
11.8.1 FormyconAG Company Information
11.8.2 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.8.3 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 FormyconAG Main Business Overview
11.8.5 FormyconAG Latest Developments
11.9 Alvotech
11.9.1 Alvotech Company Information
11.9.2 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.9.3 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Alvotech Main Business Overview
11.9.5 Alvotech Latest Developments
11.10 TevaPharmaceuticalIndustriesLtd.
11.10.1 TevaPharmaceuticalIndustriesLtd. Company Information
11.10.2 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.10.3 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 TevaPharmaceuticalIndustriesLtd. Main Business Overview
11.10.5 TevaPharmaceuticalIndustriesLtd. Latest Developments
11.11 Organon&Co.
11.11.1 Organon&Co. Company Information
11.11.2 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.11.3 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Organon&Co. Main Business Overview
11.11.5 Organon&Co. Latest Developments
11.12 BoehringerIngelheimInternationalGmbH
11.12.1 BoehringerIngelheimInternationalGmbH Company Information
11.12.2 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.12.3 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 BoehringerIngelheimInternationalGmbH Main Business Overview
11.12.5 BoehringerIngelheimInternationalGmbH Latest Developments
11.13 CoherusBioSciences,Inc.
11.13.1 CoherusBioSciences,Inc. Company Information
11.13.2 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.13.3 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 CoherusBioSciences,Inc. Main Business Overview
11.13.5 CoherusBioSciences,Inc. Latest Developments
11.14 mAbxience
11.14.1 mAbxience Company Information
11.14.2 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.14.3 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 mAbxience Main Business Overview
11.14.5 mAbxience Latest Developments
11.15 STADAArzneimittelAG
11.15.1 STADAArzneimittelAG Company Information
11.15.2 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.15.3 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 STADAArzneimittelAG Main Business Overview
11.15.5 STADAArzneimittelAG Latest Developments
11.16 GedeonRichterPlc.
11.16.1 GedeonRichterPlc. Company Information
11.16.2 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.16.3 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 GedeonRichterPlc. Main Business Overview
11.16.5 GedeonRichterPlc. Latest Developments
11.17 Bio-TheraSolutions,Ltd.
11.17.1 Bio-TheraSolutions,Ltd. Company Information
11.17.2 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.17.3 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Bio-TheraSolutions,Ltd. Main Business Overview
11.17.5 Bio-TheraSolutions,Ltd. Latest Developments
11.18 ShanghaiHenliusBiotech,Inc.
11.18.1 ShanghaiHenliusBiotech,Inc. Company Information
11.18.2 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.18.3 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 ShanghaiHenliusBiotech,Inc. Main Business Overview
11.18.5 ShanghaiHenliusBiotech,Inc. Latest Developments
11.19 QiluPharmaceuticalCo.,Ltd.
11.19.1 QiluPharmaceuticalCo.,Ltd. Company Information
11.19.2 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.19.3 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 QiluPharmaceuticalCo.,Ltd. Main Business Overview
11.19.5 QiluPharmaceuticalCo.,Ltd. Latest Developments
11.20 InnoventBiologics,Inc.
11.20.1 InnoventBiologics,Inc. Company Information
11.20.2 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.20.3 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 InnoventBiologics,Inc. Main Business Overview
11.20.5 InnoventBiologics,Inc. Latest Developments
11.21 Dr.Reddy?sLaboratoriesLtd.
11.21.1 Dr.Reddy?sLaboratoriesLtd. Company Information
11.21.2 Dr.Reddy?sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.21.3 Dr.Reddy?sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Dr.Reddy?sLaboratoriesLtd. Main Business Overview
11.21.5 Dr.Reddy?sLaboratoriesLtd. Latest Developments
11.22 IntasPharmaceuticalsLtd.
11.22.1 IntasPharmaceuticalsLtd. Company Information
11.22.2 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.22.3 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 IntasPharmaceuticalsLtd. Main Business Overview
11.22.5 IntasPharmaceuticalsLtd. Latest Developments
11.23 AccordHealthcare
11.23.1 AccordHealthcare Company Information
11.23.2 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.23.3 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 AccordHealthcare Main Business Overview
11.23.5 AccordHealthcare Latest Developments
11.24 LupinLimited
11.24.1 LupinLimited Company Information
11.24.2 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.24.3 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 LupinLimited Main Business Overview
11.24.5 LupinLimited Latest Developments
11.25 ZydusLifesciencesLimited
11.25.1 ZydusLifesciencesLimited Company Information
11.25.2 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.25.3 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 ZydusLifesciencesLimited Main Business Overview
11.25.5 ZydusLifesciencesLimited Latest Developments
11.26 RelianceLifeSciencesPvt.Ltd.
11.26.1 RelianceLifeSciencesPvt.Ltd. Company Information
11.26.2 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.26.3 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.26.4 RelianceLifeSciencesPvt.Ltd. Main Business Overview
11.26.5 RelianceLifeSciencesPvt.Ltd. Latest Developments
11.27 PrestigeBiopharmaLimited
11.27.1 PrestigeBiopharmaLimited Company Information
11.27.2 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.27.3 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.27.4 PrestigeBiopharmaLimited Main Business Overview
11.27.5 PrestigeBiopharmaLimited Latest Developments
11.28 AmnealPharmaceuticals,Inc.
11.28.1 AmnealPharmaceuticals,Inc. Company Information
11.28.2 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.28.3 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.28.4 AmnealPharmaceuticals,Inc. Main Business Overview
11.28.5 AmnealPharmaceuticals,Inc. Latest Developments
11.29 PolpharmaBiologicsB.V.
11.29.1 PolpharmaBiologicsB.V. Company Information
11.29.2 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.29.3 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.29.4 PolpharmaBiologicsB.V. Main Business Overview
11.29.5 PolpharmaBiologicsB.V. Latest Developments
11.30 Mabwell(Shanghai)BioscienceCo.,Ltd.
11.30.1 Mabwell(Shanghai)BioscienceCo.,Ltd. Company Information
11.30.2 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.30.3 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.30.4 Mabwell(Shanghai)BioscienceCo.,Ltd. Main Business Overview
11.30.5 Mabwell(Shanghai)BioscienceCo.,Ltd. Latest Developments
11.31 ZhejiangHisunPharmaceuticalCo.,Ltd.
11.31.1 ZhejiangHisunPharmaceuticalCo.,Ltd. Company Information
11.31.2 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.31.3 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.31.4 ZhejiangHisunPharmaceuticalCo.,Ltd. Main Business Overview
11.31.5 ZhejiangHisunPharmaceuticalCo.,Ltd. Latest Developments
11.32 JiangsuHengruiPharmaceuticalsCo.,Ltd.
11.32.1 JiangsuHengruiPharmaceuticalsCo.,Ltd. Company Information
11.32.2 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.32.3 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.32.4 JiangsuHengruiPharmaceuticalsCo.,Ltd. Main Business Overview
11.32.5 JiangsuHengruiPharmaceuticalsCo.,Ltd. Latest Developments
11.33 LivzonPharmaceuticalGroupInc.
11.33.1 LivzonPharmaceuticalGroupInc. Company Information
11.33.2 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.33.3 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.33.4 LivzonPharmaceuticalGroupInc. Main Business Overview
11.33.5 LivzonPharmaceuticalGroupInc. Latest Developments
11.34 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
11.34.1 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Company Information
11.34.2 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.34.3 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.34.4 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Main Business Overview
11.34.5 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Latest Developments
11.35 MabpharmLimited
11.35.1 MabpharmLimited Company Information
11.35.2 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.35.3 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.35.4 MabpharmLimited Main Business Overview
11.35.5 MabpharmLimited Latest Developments
11.36 BioXpressTherapeuticsSA
11.36.1 BioXpressTherapeuticsSA Company Information
11.36.2 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.36.3 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.36.4 BioXpressTherapeuticsSA Main Business Overview
11.36.5 BioXpressTherapeuticsSA Latest Developments
11.37 TanvexBioPharma,Inc.
11.37.1 TanvexBioPharma,Inc. Company Information
11.37.2 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.37.3 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.37.4 TanvexBioPharma,Inc. Main Business Overview
11.37.5 TanvexBioPharma,Inc. Latest Developments
11.38 CelltrionHealthcare
11.38.1 CelltrionHealthcare Company Information
11.38.2 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.38.3 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.38.4 CelltrionHealthcare Main Business Overview
11.38.5 CelltrionHealthcare Latest Developments
11.39 AmegaBiotech
11.39.1 AmegaBiotech Company Information
11.39.2 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.39.3 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.39.4 AmegaBiotech Main Business Overview
11.39.5 AmegaBiotech Latest Developments
11.40 ProbiomedS.A.deC.V.
11.40.1 ProbiomedS.A.deC.V. Company Information
11.40.2 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
11.40.3 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
11.40.4 ProbiomedS.A.deC.V. Main Business Overview
11.40.5 ProbiomedS.A.deC.V. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Monoclonal Antibodies (mAbs) Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Adalimumab Biosimilars
Table 4. Major Players of Infliximab Biosimilars
Table 5. Major Players of Rituximab Biosimilars
Table 6. Major Players of Trastuzumab Biosimilars
Table 7. Major Players of Bevacizumab Biosimilars
Table 8. Major Players of Ranibizumab Biosimilars
Table 9. Major Players of Ustekinumab Biosimilars
Table 10. Major Players of Tocilizumab Biosimilars
Table 11. Major Players of Denosumab Biosimilars
Table 12. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 14. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Table 15. Major Players of Intravenous Infusion Vials
Table 16. Major Players of Subcutaneous Prefilled Syringes
Table 17. Major Players of Autoinjectors
Table 18. Major Players of Lyophilized Powder for Injection
Table 19. Major Players of Concentrate for Solution for Infusion
Table 20. Major Players of Ophthalmic Intravitreal Injection
Table 21. Major Players of Multiple Presentations
Table 22. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Dosage Form (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form (2021-2026) & ($ millions)
Table 24. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form (2021-2026)
Table 25. Major Players of TNF-? Inhibitors
Table 26. Major Players of CD20-targeting Antibodies
Table 27. Major Players of HER2-targeting Antibodies
Table 28. Major Players of VEGF/VEGF-A Inhibitors
Table 29. Major Players of IL-6R Inhibitors
Table 30. Major Players of IL-12/23 Inhibitors
Table 31. Major Players of RANKL Inhibitors
Table 32. Major Players of C5 Complement Inhibitors
Table 33. Major Players of IgE Inhibitors
Table 34. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Molecular Target (2021 VS 2025 VS 2032) & ($ millions)
Table 35. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target (2021-2026) & ($ millions)
Table 36. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target (2021-2026)
Table 37. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 38. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 39. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Table 40. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue by Player (2021-2026) & ($ millions)
Table 41. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Player (2021-2026)
Table 42. Monoclonal Antibodies (mAbs) Biosimilars Key Players Head office and Products Offered
Table 43. Monoclonal Antibodies (mAbs) Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Mergers & Acquisitions, Expansion
Table 46. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026) & ($ millions)
Table 47. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region (2021-2026)
Table 48. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country (2021-2026) & ($ millions)
Table 51. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Country (2021-2026)
Table 52. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 53. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Table 54. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 55. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Table 56. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026) & ($ millions)
Table 57. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region (2021-2026)
Table 58. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 59. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 60. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country (2021-2026) & ($ millions)
Table 61. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Country (2021-2026)
Table 62. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 63. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 64. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026) & ($ millions)
Table 65. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 66. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 67. Key Market Drivers & Growth Opportunities of Monoclonal Antibodies (mAbs) Biosimilars
Table 68. Key Market Challenges & Risks of Monoclonal Antibodies (mAbs) Biosimilars
Table 69. Key Industry Trends of Monoclonal Antibodies (mAbs) Biosimilars
Table 70. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Forecast by Region (2027-2032) & ($ millions)
Table 71. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share Forecast by Region (2027-2032)
Table 72. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Forecast by Application (2027-2032) & ($ millions)
Table 74. Celltrion,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 75. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 76. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Celltrion,Inc. Main Business
Table 78. Celltrion,Inc. Latest Developments
Table 79. SamsungBioepisCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 80. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 81. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. SamsungBioepisCo.,Ltd. Main Business
Table 83. SamsungBioepisCo.,Ltd. Latest Developments
Table 84. AmgenInc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 85. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 86. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. AmgenInc. Main Business
Table 88. AmgenInc. Latest Developments
Table 89. SandozGroupAG Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 90. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 91. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. SandozGroupAG Main Business
Table 93. SandozGroupAG Latest Developments
Table 94. PfizerInc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 95. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 96. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. PfizerInc. Main Business
Table 98. PfizerInc. Latest Developments
Table 99. BioconBiologicsLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 100. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 101. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. BioconBiologicsLimited Main Business
Table 103. BioconBiologicsLimited Latest Developments
Table 104. FreseniusKabiAG Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 105. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 106. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. FreseniusKabiAG Main Business
Table 108. FreseniusKabiAG Latest Developments
Table 109. FormyconAG Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 110. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 111. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. FormyconAG Main Business
Table 113. FormyconAG Latest Developments
Table 114. Alvotech Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 115. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 116. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. Alvotech Main Business
Table 118. Alvotech Latest Developments
Table 119. TevaPharmaceuticalIndustriesLtd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 120. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 121. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. TevaPharmaceuticalIndustriesLtd. Main Business
Table 123. TevaPharmaceuticalIndustriesLtd. Latest Developments
Table 124. Organon&Co. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 125. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 126. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Organon&Co. Main Business
Table 128. Organon&Co. Latest Developments
Table 129. BoehringerIngelheimInternationalGmbH Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 130. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 131. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 132. BoehringerIngelheimInternationalGmbH Main Business
Table 133. BoehringerIngelheimInternationalGmbH Latest Developments
Table 134. CoherusBioSciences,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 135. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 136. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 137. CoherusBioSciences,Inc. Main Business
Table 138. CoherusBioSciences,Inc. Latest Developments
Table 139. mAbxience Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 140. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 141. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 142. mAbxience Main Business
Table 143. mAbxience Latest Developments
Table 144. STADAArzneimittelAG Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 145. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 146. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 147. STADAArzneimittelAG Main Business
Table 148. STADAArzneimittelAG Latest Developments
Table 149. GedeonRichterPlc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 150. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 151. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 152. GedeonRichterPlc. Main Business
Table 153. GedeonRichterPlc. Latest Developments
Table 154. Bio-TheraSolutions,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 155. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 156. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 157. Bio-TheraSolutions,Ltd. Main Business
Table 158. Bio-TheraSolutions,Ltd. Latest Developments
Table 159. ShanghaiHenliusBiotech,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 160. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 161. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 162. ShanghaiHenliusBiotech,Inc. Main Business
Table 163. ShanghaiHenliusBiotech,Inc. Latest Developments
Table 164. QiluPharmaceuticalCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 165. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 166. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 167. QiluPharmaceuticalCo.,Ltd. Main Business
Table 168. QiluPharmaceuticalCo.,Ltd. Latest Developments
Table 169. InnoventBiologics,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 170. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 171. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 172. InnoventBiologics,Inc. Main Business
Table 173. InnoventBiologics,Inc. Latest Developments
Table 174. Dr.Reddy?sLaboratoriesLtd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 175. Dr.Reddy?sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 176. Dr.Reddy?sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 177. Dr.Reddy?sLaboratoriesLtd. Main Business
Table 178. Dr.Reddy?sLaboratoriesLtd. Latest Developments
Table 179. IntasPharmaceuticalsLtd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 180. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 181. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 182. IntasPharmaceuticalsLtd. Main Business
Table 183. IntasPharmaceuticalsLtd. Latest Developments
Table 184. AccordHealthcare Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 185. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 186. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 187. AccordHealthcare Main Business
Table 188. AccordHealthcare Latest Developments
Table 189. LupinLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 190. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 191. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 192. LupinLimited Main Business
Table 193. LupinLimited Latest Developments
Table 194. ZydusLifesciencesLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 195. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 196. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 197. ZydusLifesciencesLimited Main Business
Table 198. ZydusLifesciencesLimited Latest Developments
Table 199. RelianceLifeSciencesPvt.Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 200. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 201. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 202. RelianceLifeSciencesPvt.Ltd. Main Business
Table 203. RelianceLifeSciencesPvt.Ltd. Latest Developments
Table 204. PrestigeBiopharmaLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 205. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 206. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 207. PrestigeBiopharmaLimited Main Business
Table 208. PrestigeBiopharmaLimited Latest Developments
Table 209. AmnealPharmaceuticals,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 210. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 211. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 212. AmnealPharmaceuticals,Inc. Main Business
Table 213. AmnealPharmaceuticals,Inc. Latest Developments
Table 214. PolpharmaBiologicsB.V. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 215. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 216. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 217. PolpharmaBiologicsB.V. Main Business
Table 218. PolpharmaBiologicsB.V. Latest Developments
Table 219. Mabwell(Shanghai)BioscienceCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 220. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 221. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 222. Mabwell(Shanghai)BioscienceCo.,Ltd. Main Business
Table 223. Mabwell(Shanghai)BioscienceCo.,Ltd. Latest Developments
Table 224. ZhejiangHisunPharmaceuticalCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 225. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 226. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 227. ZhejiangHisunPharmaceuticalCo.,Ltd. Main Business
Table 228. ZhejiangHisunPharmaceuticalCo.,Ltd. Latest Developments
Table 229. JiangsuHengruiPharmaceuticalsCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 230. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 231. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 232. JiangsuHengruiPharmaceuticalsCo.,Ltd. Main Business
Table 233. JiangsuHengruiPharmaceuticalsCo.,Ltd. Latest Developments
Table 234. LivzonPharmaceuticalGroupInc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 235. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 236. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 237. LivzonPharmaceuticalGroupInc. Main Business
Table 238. LivzonPharmaceuticalGroupInc. Latest Developments
Table 239. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 240. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 241. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 242. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Main Business
Table 243. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Latest Developments
Table 244. MabpharmLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 245. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 246. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 247. MabpharmLimited Main Business
Table 248. MabpharmLimited Latest Developments
Table 249. BioXpressTherapeuticsSA Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 250. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 251. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 252. BioXpressTherapeuticsSA Main Business
Table 253. BioXpressTherapeuticsSA Latest Developments
Table 254. TanvexBioPharma,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 255. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 256. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 257. TanvexBioPharma,Inc. Main Business
Table 258. TanvexBioPharma,Inc. Latest Developments
Table 259. CelltrionHealthcare Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 260. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 261. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 262. CelltrionHealthcare Main Business
Table 263. CelltrionHealthcare Latest Developments
Table 264. AmegaBiotech Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 265. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 266. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 267. AmegaBiotech Main Business
Table 268. AmegaBiotech Latest Developments
Table 269. ProbiomedS.A.deC.V. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 270. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 271. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 272. ProbiomedS.A.deC.V. Main Business
Table 273. ProbiomedS.A.deC.V. Latest Developments
Table 1. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Monoclonal Antibodies (mAbs) Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Adalimumab Biosimilars
Table 4. Major Players of Infliximab Biosimilars
Table 5. Major Players of Rituximab Biosimilars
Table 6. Major Players of Trastuzumab Biosimilars
Table 7. Major Players of Bevacizumab Biosimilars
Table 8. Major Players of Ranibizumab Biosimilars
Table 9. Major Players of Ustekinumab Biosimilars
Table 10. Major Players of Tocilizumab Biosimilars
Table 11. Major Players of Denosumab Biosimilars
Table 12. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 14. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Table 15. Major Players of Intravenous Infusion Vials
Table 16. Major Players of Subcutaneous Prefilled Syringes
Table 17. Major Players of Autoinjectors
Table 18. Major Players of Lyophilized Powder for Injection
Table 19. Major Players of Concentrate for Solution for Infusion
Table 20. Major Players of Ophthalmic Intravitreal Injection
Table 21. Major Players of Multiple Presentations
Table 22. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Dosage Form (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form (2021-2026) & ($ millions)
Table 24. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form (2021-2026)
Table 25. Major Players of TNF-? Inhibitors
Table 26. Major Players of CD20-targeting Antibodies
Table 27. Major Players of HER2-targeting Antibodies
Table 28. Major Players of VEGF/VEGF-A Inhibitors
Table 29. Major Players of IL-6R Inhibitors
Table 30. Major Players of IL-12/23 Inhibitors
Table 31. Major Players of RANKL Inhibitors
Table 32. Major Players of C5 Complement Inhibitors
Table 33. Major Players of IgE Inhibitors
Table 34. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Molecular Target (2021 VS 2025 VS 2032) & ($ millions)
Table 35. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target (2021-2026) & ($ millions)
Table 36. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target (2021-2026)
Table 37. Monoclonal Antibodies (mAbs) Biosimilars Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 38. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 39. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Table 40. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue by Player (2021-2026) & ($ millions)
Table 41. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Player (2021-2026)
Table 42. Monoclonal Antibodies (mAbs) Biosimilars Key Players Head office and Products Offered
Table 43. Monoclonal Antibodies (mAbs) Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Mergers & Acquisitions, Expansion
Table 46. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026) & ($ millions)
Table 47. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region (2021-2026)
Table 48. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country (2021-2026) & ($ millions)
Table 51. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Country (2021-2026)
Table 52. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 53. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Table 54. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 55. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Table 56. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026) & ($ millions)
Table 57. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region (2021-2026)
Table 58. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 59. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 60. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country (2021-2026) & ($ millions)
Table 61. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Country (2021-2026)
Table 62. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 63. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 64. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2026) & ($ millions)
Table 65. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026) & ($ millions)
Table 66. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & ($ millions)
Table 67. Key Market Drivers & Growth Opportunities of Monoclonal Antibodies (mAbs) Biosimilars
Table 68. Key Market Challenges & Risks of Monoclonal Antibodies (mAbs) Biosimilars
Table 69. Key Industry Trends of Monoclonal Antibodies (mAbs) Biosimilars
Table 70. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Forecast by Region (2027-2032) & ($ millions)
Table 71. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share Forecast by Region (2027-2032)
Table 72. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Forecast by Application (2027-2032) & ($ millions)
Table 74. Celltrion,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 75. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 76. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Celltrion,Inc. Main Business
Table 78. Celltrion,Inc. Latest Developments
Table 79. SamsungBioepisCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 80. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 81. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. SamsungBioepisCo.,Ltd. Main Business
Table 83. SamsungBioepisCo.,Ltd. Latest Developments
Table 84. AmgenInc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 85. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 86. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. AmgenInc. Main Business
Table 88. AmgenInc. Latest Developments
Table 89. SandozGroupAG Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 90. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 91. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. SandozGroupAG Main Business
Table 93. SandozGroupAG Latest Developments
Table 94. PfizerInc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 95. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 96. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. PfizerInc. Main Business
Table 98. PfizerInc. Latest Developments
Table 99. BioconBiologicsLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 100. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 101. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. BioconBiologicsLimited Main Business
Table 103. BioconBiologicsLimited Latest Developments
Table 104. FreseniusKabiAG Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 105. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 106. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. FreseniusKabiAG Main Business
Table 108. FreseniusKabiAG Latest Developments
Table 109. FormyconAG Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 110. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 111. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. FormyconAG Main Business
Table 113. FormyconAG Latest Developments
Table 114. Alvotech Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 115. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 116. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. Alvotech Main Business
Table 118. Alvotech Latest Developments
Table 119. TevaPharmaceuticalIndustriesLtd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 120. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 121. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. TevaPharmaceuticalIndustriesLtd. Main Business
Table 123. TevaPharmaceuticalIndustriesLtd. Latest Developments
Table 124. Organon&Co. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 125. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 126. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Organon&Co. Main Business
Table 128. Organon&Co. Latest Developments
Table 129. BoehringerIngelheimInternationalGmbH Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 130. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 131. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 132. BoehringerIngelheimInternationalGmbH Main Business
Table 133. BoehringerIngelheimInternationalGmbH Latest Developments
Table 134. CoherusBioSciences,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 135. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 136. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 137. CoherusBioSciences,Inc. Main Business
Table 138. CoherusBioSciences,Inc. Latest Developments
Table 139. mAbxience Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 140. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 141. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 142. mAbxience Main Business
Table 143. mAbxience Latest Developments
Table 144. STADAArzneimittelAG Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 145. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 146. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 147. STADAArzneimittelAG Main Business
Table 148. STADAArzneimittelAG Latest Developments
Table 149. GedeonRichterPlc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 150. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 151. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 152. GedeonRichterPlc. Main Business
Table 153. GedeonRichterPlc. Latest Developments
Table 154. Bio-TheraSolutions,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 155. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 156. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 157. Bio-TheraSolutions,Ltd. Main Business
Table 158. Bio-TheraSolutions,Ltd. Latest Developments
Table 159. ShanghaiHenliusBiotech,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 160. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 161. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 162. ShanghaiHenliusBiotech,Inc. Main Business
Table 163. ShanghaiHenliusBiotech,Inc. Latest Developments
Table 164. QiluPharmaceuticalCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 165. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 166. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 167. QiluPharmaceuticalCo.,Ltd. Main Business
Table 168. QiluPharmaceuticalCo.,Ltd. Latest Developments
Table 169. InnoventBiologics,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 170. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 171. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 172. InnoventBiologics,Inc. Main Business
Table 173. InnoventBiologics,Inc. Latest Developments
Table 174. Dr.Reddy?sLaboratoriesLtd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 175. Dr.Reddy?sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 176. Dr.Reddy?sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 177. Dr.Reddy?sLaboratoriesLtd. Main Business
Table 178. Dr.Reddy?sLaboratoriesLtd. Latest Developments
Table 179. IntasPharmaceuticalsLtd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 180. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 181. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 182. IntasPharmaceuticalsLtd. Main Business
Table 183. IntasPharmaceuticalsLtd. Latest Developments
Table 184. AccordHealthcare Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 185. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 186. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 187. AccordHealthcare Main Business
Table 188. AccordHealthcare Latest Developments
Table 189. LupinLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 190. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 191. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 192. LupinLimited Main Business
Table 193. LupinLimited Latest Developments
Table 194. ZydusLifesciencesLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 195. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 196. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 197. ZydusLifesciencesLimited Main Business
Table 198. ZydusLifesciencesLimited Latest Developments
Table 199. RelianceLifeSciencesPvt.Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 200. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 201. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 202. RelianceLifeSciencesPvt.Ltd. Main Business
Table 203. RelianceLifeSciencesPvt.Ltd. Latest Developments
Table 204. PrestigeBiopharmaLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 205. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 206. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 207. PrestigeBiopharmaLimited Main Business
Table 208. PrestigeBiopharmaLimited Latest Developments
Table 209. AmnealPharmaceuticals,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 210. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 211. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 212. AmnealPharmaceuticals,Inc. Main Business
Table 213. AmnealPharmaceuticals,Inc. Latest Developments
Table 214. PolpharmaBiologicsB.V. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 215. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 216. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 217. PolpharmaBiologicsB.V. Main Business
Table 218. PolpharmaBiologicsB.V. Latest Developments
Table 219. Mabwell(Shanghai)BioscienceCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 220. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 221. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 222. Mabwell(Shanghai)BioscienceCo.,Ltd. Main Business
Table 223. Mabwell(Shanghai)BioscienceCo.,Ltd. Latest Developments
Table 224. ZhejiangHisunPharmaceuticalCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 225. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 226. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 227. ZhejiangHisunPharmaceuticalCo.,Ltd. Main Business
Table 228. ZhejiangHisunPharmaceuticalCo.,Ltd. Latest Developments
Table 229. JiangsuHengruiPharmaceuticalsCo.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 230. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 231. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 232. JiangsuHengruiPharmaceuticalsCo.,Ltd. Main Business
Table 233. JiangsuHengruiPharmaceuticalsCo.,Ltd. Latest Developments
Table 234. LivzonPharmaceuticalGroupInc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 235. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 236. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 237. LivzonPharmaceuticalGroupInc. Main Business
Table 238. LivzonPharmaceuticalGroupInc. Latest Developments
Table 239. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 240. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 241. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 242. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Main Business
Table 243. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Latest Developments
Table 244. MabpharmLimited Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 245. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 246. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 247. MabpharmLimited Main Business
Table 248. MabpharmLimited Latest Developments
Table 249. BioXpressTherapeuticsSA Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 250. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 251. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 252. BioXpressTherapeuticsSA Main Business
Table 253. BioXpressTherapeuticsSA Latest Developments
Table 254. TanvexBioPharma,Inc. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 255. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 256. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 257. TanvexBioPharma,Inc. Main Business
Table 258. TanvexBioPharma,Inc. Latest Developments
Table 259. CelltrionHealthcare Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 260. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 261. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 262. CelltrionHealthcare Main Business
Table 263. CelltrionHealthcare Latest Developments
Table 264. AmegaBiotech Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 265. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 266. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 267. AmegaBiotech Main Business
Table 268. AmegaBiotech Latest Developments
Table 269. ProbiomedS.A.deC.V. Details, Company Type, Monoclonal Antibodies (mAbs) Biosimilars Area Served and Its Competitors
Table 270. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offered
Table 271. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 272. ProbiomedS.A.deC.V. Main Business
Table 273. ProbiomedS.A.deC.V. Latest Developments
LIST OF FIGURES
Figure 1. Monoclonal Antibodies (mAbs) Biosimilars Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Monoclonal Antibodies (mAbs) Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Monoclonal Antibodies (mAbs) Biosimilars Sales Market Share by Country/Region (2025)
Figure 8. Monoclonal Antibodies (mAbs) Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type in 2025
Figure 10. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form in 2025
Figure 11. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target in 2025
Figure 12. Monoclonal Antibodies (mAbs) Biosimilars in Oncology
Figure 13. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Oncology (2021-2026) & ($ millions)
Figure 14. Monoclonal Antibodies (mAbs) Biosimilars in Autoimmune and Inflammatory Diseases
Figure 15. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Autoimmune and Inflammatory Diseases (2021-2026) & ($ millions)
Figure 16. Monoclonal Antibodies (mAbs) Biosimilars in Ophthalmology
Figure 17. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Ophthalmology (2021-2026) & ($ millions)
Figure 18. Monoclonal Antibodies (mAbs) Biosimilars in Bone Disease and Osteoporosis
Figure 19. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Bone Disease and Osteoporosis (2021-2026) & ($ millions)
Figure 20. Monoclonal Antibodies (mAbs) Biosimilars in Hematology and Rare Diseases
Figure 21. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Hematology and Rare Diseases (2021-2026) & ($ millions)
Figure 22. Monoclonal Antibodies (mAbs) Biosimilars in Asthma and Allergy
Figure 23. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Asthma and Allergy (2021-2026) & ($ millions)
Figure 24. Monoclonal Antibodies (mAbs) Biosimilars in Other
Figure 25. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Other (2021-2026) & ($ millions)
Figure 26. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application in 2025
Figure 27. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Player in 2025
Figure 28. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region (2021-2026)
Figure 29. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size 2021-2026 ($ millions)
Figure 30. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size 2021-2026 ($ millions)
Figure 31. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size 2021-2026 ($ millions)
Figure 32. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size 2021-2026 ($ millions)
Figure 33. Americas Monoclonal Antibodies (mAbs) Biosimilars Value Market Share by Country in 2025
Figure 34. United States Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 35. Canada Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 36. Mexico Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 37. Brazil Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 38. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region in 2025
Figure 39. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Figure 40. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Figure 41. China Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 42. Japan Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 43. South Korea Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 44. Southeast Asia Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 45. India Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 46. Australia Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 47. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Country in 2025
Figure 48. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Figure 49. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Figure 50. Germany Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 51. France Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 52. UK Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 53. Italy Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 54. Russia Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 55. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region (2021-2026)
Figure 56. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Figure 57. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Figure 58. Egypt Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 59. South Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 60. Israel Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 61. Turkey Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 62. GCC Countries Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 63. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 64. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 65. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 66. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 67. United States Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 68. Canada Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 69. Mexico Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 70. Brazil Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 71. China Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 72. Japan Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 73. Korea Monoclonal Antibodies (mAbs) Biosimilars Market
Figure 1. Monoclonal Antibodies (mAbs) Biosimilars Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Monoclonal Antibodies (mAbs) Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Monoclonal Antibodies (mAbs) Biosimilars Sales Market Share by Country/Region (2025)
Figure 8. Monoclonal Antibodies (mAbs) Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type in 2025
Figure 10. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form in 2025
Figure 11. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target in 2025
Figure 12. Monoclonal Antibodies (mAbs) Biosimilars in Oncology
Figure 13. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Oncology (2021-2026) & ($ millions)
Figure 14. Monoclonal Antibodies (mAbs) Biosimilars in Autoimmune and Inflammatory Diseases
Figure 15. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Autoimmune and Inflammatory Diseases (2021-2026) & ($ millions)
Figure 16. Monoclonal Antibodies (mAbs) Biosimilars in Ophthalmology
Figure 17. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Ophthalmology (2021-2026) & ($ millions)
Figure 18. Monoclonal Antibodies (mAbs) Biosimilars in Bone Disease and Osteoporosis
Figure 19. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Bone Disease and Osteoporosis (2021-2026) & ($ millions)
Figure 20. Monoclonal Antibodies (mAbs) Biosimilars in Hematology and Rare Diseases
Figure 21. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Hematology and Rare Diseases (2021-2026) & ($ millions)
Figure 22. Monoclonal Antibodies (mAbs) Biosimilars in Asthma and Allergy
Figure 23. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Asthma and Allergy (2021-2026) & ($ millions)
Figure 24. Monoclonal Antibodies (mAbs) Biosimilars in Other
Figure 25. Global Monoclonal Antibodies (mAbs) Biosimilars Market: Other (2021-2026) & ($ millions)
Figure 26. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application in 2025
Figure 27. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Player in 2025
Figure 28. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region (2021-2026)
Figure 29. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size 2021-2026 ($ millions)
Figure 30. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size 2021-2026 ($ millions)
Figure 31. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size 2021-2026 ($ millions)
Figure 32. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size 2021-2026 ($ millions)
Figure 33. Americas Monoclonal Antibodies (mAbs) Biosimilars Value Market Share by Country in 2025
Figure 34. United States Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 35. Canada Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 36. Mexico Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 37. Brazil Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 38. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region in 2025
Figure 39. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Figure 40. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Figure 41. China Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 42. Japan Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 43. South Korea Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 44. Southeast Asia Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 45. India Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 46. Australia Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 47. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Country in 2025
Figure 48. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Figure 49. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Figure 50. Germany Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 51. France Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 52. UK Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 53. Italy Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 54. Russia Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 55. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Region (2021-2026)
Figure 56. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2026)
Figure 57. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2026)
Figure 58. Egypt Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 59. South Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 60. Israel Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 61. Turkey Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 62. GCC Countries Monoclonal Antibodies (mAbs) Biosimilars Market Size Growth 2021-2026 ($ millions)
Figure 63. Americas Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 64. APAC Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 65. Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 66. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 67. United States Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 68. Canada Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 69. Mexico Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 70. Brazil Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 71. China Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 72. Japan Monoclonal Antibodies (mAbs) Biosimilars Market Size 2027-2032 ($ millions)
Figure 73. Korea Monoclonal Antibodies (mAbs) Biosimilars Market
